Biomarkers for diagnosing alzheimer&#39;s disease

ABSTRACT

A method for assessing the state of Alzheimer&#39;s disease in patients is disclosed. A method for monitoring the progression of Alzheimer&#39;s disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.

FIELD OF THE INVENTION

The invention is in the field of diagnostics. More specifically, theinvention is in the field of assessing the state of Alzheimer's diseasein subjects by detection of Alzheimer's disease-specific markerpolypeptides.

BACKGROUND OF THE INVENTION

Alzheimer's disease

Alzheimer's disease is an increasingly prevalent form ofneurodegeneration that accounts for approximately 50-60% of the overallcases of dementia among people over 65 years of age. Pathologically,Alzheimer's disease neurodegeneration is characterised by prominentatrophy of corticolimbic structures with neuronal death and loss ofneuronal synapses, neurofibrillary tangle (NFT) formation, and theformation of senile plaques containing deposits of amyloid β1-42 (Aβ42)aggregates in the brain [Francis PT 1999]. The duration of theprogressive cognitive decline is approximately 7 years from theoccurrence of first signs until death. It is assumed that the clinicalphase is preceded by a 15-30 years preclinical period of continuousdeposition of amyloid plaques and neurofibrillary tangles. Age of onsetand progression of the disease are largely determined by causative genemutations and by genetic susceptibility factors. Several environmentalrisk factors may add to the individual genetic risk factors. Geneticfactors known to be involved in the familial form of Alzheimer's diseasewith early onset of the disease are: mutations in presenilin 1 (PS1),presenilin 2 (PS2), and amyloid precursor protein (APP) genes, and thepresence of the apolipoprotein E4 allele. However, the majority (95%) ofAlzheimer's disease cases is sporadic and heterogeneous.

Currently, clinical diagnosis of Alzheimer's disease can only beestablished at later stages of the disease, when cognitive performanceis significantly decreased and paralleled by structural alterations ofthe brain. The clinical diagnostic work up requires a careful medicalhistory; physical and neurological examination; blood, urine andcerebrospinal fluid (CSF) examinations to exclude metabolic and medicaldisease states that might masquerade Alzheimer's disease; detailedpsychometric examinations to assess mental status and cognitiveperformance, and imaging techniques such as computed tomographic scan ormagnetic resonance imaging of the brain. Diagnostic evaluations atexpert centres reach an accuracy of about 80-85%. Due to the fact thatthese tests are expensive and time consuming, and are particularlyinconvenient to patients, there is an increasing need foreasy-accessible specific diagnostic biomolecule markers, which can bemeasured in body fluids, such as CSF, blood or urine, and which have ahigh positive predictive value for diagnosis of Alzheimer's disease, orwould help to distinguish Alzheimer's disease from other forms ofdementia. Furthermore, reliable markers sensitive to disease progressionmay constitute surrogate parameters, a major prerequisite for theevaluation and development of new causal oriented and disease modifyingtherapeutic strategies in Alzheimer's disease.

Since CSF directly surrounds the brain, changes in its proteincomposition may most accurately reflect pathologic conditions that areassociated with specific alterations of the protein expression patterns.Over the last decade, a number of biological abnormalities have beenreported in the cerebrospinal fluid (CSF) of Alzheimer's diseasepatients, in particular altered levels of the Aβ1-42 fragment of theamyloid precursor protein, and altered levels of the hyperphosphorylatedtan protein. The sensitivity and specificity of these markers, however,is low or only modest [The Ronald and Nancy Reagan Research Institue ofthe Alzheimer's Association and the National Institute on Aging WorkingGroup, 1998, Robles A 1998, Termissen C E et al., 2002].

Hence, there is a need for novel biomarkers with sufficient sensitivityand specificity for (i) detecting Alzheimer's disease as early aspossible, and (ii) to allow disease differentiation from other types ofdementia or neurodegenerative diseases, and (iii) monitoring therapeuticefficacy as surrogate parameter, e.g. in clinical drug development, andto initiate pharmacotherapy as early as possible and postpone loss ofmemory and disease progression.

Protein Chip Technology

A Protein chip technology called Surface Enhanced LaserDesorption/Ionisation time of flight mass spectrometry (SELDI-TOF MS)has recently been developed to facilitate protein profiling of complexbiological mixtures [Davies H A 2000, Fung ET 2001, Merchant M 2000].

Protein chip mass spectrometry has already been used by several groupsto detect potentially novel biomarkers of prostate and bladder [Adam B L2001] or breast cancer [Wulfkuhle I D 2001] in serum, seminal plasma,nipple fluid, urine or cell extracts. For a review on biomarker searchusing SELDI-TOF MS, see [Issaq H J 2002].

Cystatin C

Initially described in 1961 in cerebrospinal fluid (CSF), cystatin C (ytrace or post-γ globulin, Ace. No. P01034) is a small cystein proteinaseinhibitor present in all human body fluids at physiologically relevantconcentrations. The physiological role of cystatin C is likely toregulate extracellular cysteine protease activity, which results frommicrobial invasion or release of lysosomal proteinases from dying ordiseased cells. Cystatin C colocalises with β-amyloid (Aβ) within thearteriolar walls in Alzheimer's disease brains and cerebral amyloidangiopathy [Levy E 2001]. There are two common haplotypes of the CST3gene coding for cystatin C (A and B) that differ from each other atthree sites: two single base pair changes in the promoter region and onein the signal peptide domain that causes an amino acid substitution(alanine to threonine). Recently, case control studies foundassociations of CST3 with increased risk for late onset Alzheimer'sdisease [Crawford F C 2000, Finckh U 2000, Beyer K 2001].

Hereditary cerebral hemorrhage with amyloidosis, Icelandic type(HCHWA-I), also called hereditary cystatin C amyloid angiopathy (HCCAA),is an autosomal dominant form of cerebral amyloid angiopathy (CAA). Theamyloid deposited in the brain vessel's walls is composed mainly of avariant of cystatin C characterised by the presence of the Leu68-Glnsubstitution [Cohen 1983, Ghiso 1986]. This pathology is also coupled toa decreased concentration of this major cystein proteinase inhibitor incerebrospinal fluid and leads to its amyloid deposition in the brain[Grubb A O 1984].

Leung-Tack et al have also purified two N-terminal truncated isoforms ofcystatin C in urine from one patient who had received renal transplant.According to their data, (des1-4) cystatin C has an inhibiting effect ontwo functions of human peripheral mononuclear cells (PMN): O₂ ⁻ releaseand phagocytosis, which may be due to the N-terminal sequence ‘KPPR’.Their data support a potentially important role for cystatin C as apossible immunomodulator during inflammation. Accumulating evidenceindicates that increased free radical mediated damage to cellularfunction contributes to the ageing process and age-relatedneurodegenerative disorders. Oxidative stress may play a role inAlzheimer's disease, Parlcinson's disease, amyotrophic lateral sclerosis(ALS). Although free-radical damage to neurons may not be the primaryevent initiating these diseases, it appears that free-radical damage isinvolved in the pathogenetic cascade of these disorders.

Beta-2-microglobulin

Beta-2-microglobulin (Ace. No. P01884) constitutes the small constantcomponent of the class I major histocompatibility complex (CMH) and itspresence in biological fluids represents the balance between membraneprotein turnover and elimination. Since this peptide seems to beincreased in some diseases characterised by an elevation of the immuneresponse, its quantification in body fluids has become a useful index ofimmunological state in vivo [Hoelcman et al 1985]. The function of thisprotein is unclear, but it seems to be implicated in diseases, whichinvolve glial cell destruction [Ernerudh et al 1987].

The technical problem which is solved by the present invention is theprovision of improved methods for diagnosing Alzheimer's disease and/ormonitoring the progression of Alzheimer's disease in a subject.

Neurosecretary Protein (VGF)

VGF (human VGF, Acc.-No.: 015240) is a secretory peptide precursor thatis expressed and processed by neuronal cells [Canu. et al. 1997]. Insitu hybridization studies in the adult rat central nervous system haverevealed that the VGF mRNA is widely distributed throughout the brainwith prominent expression in the hippocampus, entorhinal cortex, andneocortex. Furthermore, it has been shown that VGF transcription andsecretion is selectively upregulated by neurotrophins like NGF and BDNF,and by depolarization in vitro. Increased BDNF expression can beobserved in dentate gyrus and CA3 regions of the hippocampus, which aretissues that appear to die early in Alzheimer Disease pathogenesis.

DESCRIPTION OF THE INVENTION

The invention is based on the surprising finding that specificpolypeptides are differentially expressed in subjects having Alzheimer'sdisease when compared to a healthy control group. These differentiallyexpressed polypeptides can be, e.g., detected in samples ofcerebrospinal fluid of the subject in which Alzheimer's disease is to bediagnosed. The individual polypeptides of the invention can be detectedand/or quantified alone or in combination with other polypeptides of theinvention.

The polypeptide markers of the invention are defined by their respectivemolecular weight. Five markers identified by the SAX2 method asdescribed in the Examples show the following molecular masses:

-   -   Marker 1 (M1): 4824±20 Da;    -   Marker 2 (M2): 7691±20 Da;    -   Marker 3 (M3): 11787±20 Da;    -   Marker 4 (M4): 11988±20 Da;    -   Marker 5 (M5): 13416±20 Da.

Table one shows the observed molecular weight of polypeptide markers M1to M5 as determined by SELDI-TOF MS, the amino acid sequences ofobserved fragments of polypeptide markers M1 to M5, and the protein fromwhich the polypeptide markers M1 to M5 originate.

TABLE 1 SEMI ob- Marker served MW Amino Acid Sequence Protein Name M14823.5   VGEEDEEAAEAEAEAEEAER VGF4.8 Da ± 1.7 M2 7691.4  XXAD(L/I)AGHG(Q/K)EV(L/I)(L/I) human myoglobin Da ± 4.9 R new variantHGTVV(L/I)TA(L/I)KGG(L/I)(L/I) M3 11786.9   VNHVTLSQPK human beta-2-Da ± 7.6 VEHSDLSFSK micro-globulin M4 11988.4   IEKVEHSDLSFSK Da ± 5.9SNFLNCYVSGFHPSDIEVDLLK M5 13416.4   ASNDMYHSR human Cystatin C Da ± 9.4ALDFAVGEYNK RALDFAVGEYNK LVGGPMDASVEEEGVR QIVAGVNYFLDVELGRLVGGPMDASVEEEGVRR KQIVAGVNYFLDVELGR TQPNLDNCPFHDQPPHLKTQPNLDNCPFHDQPPHLKR SSPGKPPRLVGGPMDASVEEEGVR

The differentially expressed polypeptides of the invention can be, e.g.,detected in samples of cerebrospinal fluid of the subject in whichAlzheimer's disease is to be diagnosed. In addition, depending on thespecific embodiment, the source of samples to measure the abundance ofthe polypeptide markers of the invention, can also be blood, serum, orurine, but is not limited to these body compartments.

As shown in FIG. 1, compared to a negative diagnosis (healthy controls),M1 is under-expressed in the CSF of Alzheimer's disease patients(p<0.05), while the markers M2 to M5 are over-expressed in CSF ofAlzheimer's disease patients (p<0.05).

An altered level of one or several polypeptides of the invention,compared to the level of polypeptides of the invention in healthycontrol subjects, will allow assessing the state of and/or monitoringthe progression of Alzheimer's disease in a subject, will allowmonitoring the effectiveness of Alzheimer's disease treatment, and willbe useful information for drug development. Furthermore, thesebiomolecule markers are useful for differentiating Alzheimer's diseasefrom other forms of dementia and neurodegenerative disorders.

Preferred subjects in which Alzheimer's disease is to be diagnosed ormonitored are human subjects. However, diagnosis of Alzheimer's diseaseaccording to the invention is also possible with other mammals. Ifnecessary, orthologues of the peptide markers of the invention can beused.

The invention also relates to the use of mass spectrometry (MS) fordetecting Alzheimer's disease in human subjects and for assessing theprogression of Alzheimer's disease in human subjects by detecting and/orquantifying the amount of specific polypeptides in samples drawn fromthe subject's body fluids. In a preferred embodiment of the invention,the sample is drawn from the subject's cerebrospinal fluid (CSF).

Detection and/or quantification of the polypeptides of the invention ispreferably achieved by quantifying the signal which is detected by MS atspecific molecular mass to charge ratios (M/z) which correspond to theM/z ratios of the polypeptides of the invention. Preferably, M/z ratiosclose to the one of the polypeptides of the invention are also measured.

Detection and/or quantification of the polypeptides of the invention canalso be achieved by using an immunoassay using specific antibodiesraised against the specified marker(s) or polypeptide fragments thereof.Antibodies can be prepared by using the purified marker(s) or fragmentsthereof, or using synthetic or recombinantly expressed polypeptide(s)consisting of the specific amino acid sequence of the marker(s) usingany suitable method known in the art [Coligan 1991]. Such techniquesinclude, but are not limited to, antibody preparation by selection ofantibodies from libraries of recombinant antibodies in phage orappropriate vectors, as well as preparation of polyclonal and monoclonalantibodies by immunising rabbits or mice [Huse 1989, Ward 1989]. Afterthe antibody is provided, a marker can be detected and/or quantifiedusing any of a number of standard immunological binding assays [U.S.Pat. Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168]. Useful assaysinclude, but are not limited to, for example, an enzyme immune assay(ETA) such as enzyme-linked immunosorbent assay (ELISA), a radioimmuneassay (RIA), a Western blot assay, or a slot or dot blot assay. For areview of the general immunoassays see [Coligan 1991]. Generally, asample obtained from a subject can be contacted with the antibody thatspecifically binds the marker. A powerful technique to capture thespecified marker(s) from a complex body fluid sample is to use theantibody fixed to solid supports, such as glass or plastic, e.g.microtiter plate, a stick, a bead, or microbead. Alternatively,marker(s) can also be captured from the body fluid sample by thespecific antibody immobilised to a probe substrate or a ProteinChip™array, as described for the SELDI-based immunoassay [Xiao 2001]. Afterincubating the sample with antibodies, the non-bound material is washedunder specified conditions and the antibody-marker complex formed can bedetected, using appropriate detection reagents. In an embodiment usingthe SELDI ProteinChip™ array technique the marker(s) selectivelyenriched by the immobilised antibody can be detected and quantified bymatrix-assisted laser desorption ionisation mass spectrometry.

The invention specifically relates to

-   -   1. a method of assessing the state of Alzheimer's disease in a        subject comprising detection of at least one polypeptide        comprised in a group of polypeptides consisting of        -   i) a polyp eptide having a molecular mass of 4824±20 Da,        -   ii) a polypeptide having a molecular mass of 7691±20 Da,        -   iii) a polypeptide having a molecular mass of 11787±20 Da,        -   iv) a polypeptide having a molecular mass of 11988±20 Da,            and        -   v) a polypeptide having a molecular mass of 13416±20 Da.    -   The invention further relates to a method of assessing the state        of Alzheimer's disease in a subject comprising detection of at        least one polypeptide comprised in a group of polypeptides        having, respectively, molecular masses of 4824±20 Da, of 7691±20        Da, of 11787±20 Da, of 11988±20 Da, of 13416±20 Da, of 4769±20        Da, of 6958±20 Da, of 6991±20 Da, of 13412±20 Da, of 13787±20        Da, of 17276±20 Da, of 40437±20 Da, of 6895±20 Da, of 6928±20        Da, of 7691±20 Da, of 7769±20 Da, of 7934±20 Da, of 5082±20 Da,        of 6267±20 Da, of 6518±20 Da, of 7274±20 Da, and of 8209±20 Da.    -   Whereas detection of one such polyp eptide is in most cases        sufficient to reliably diagnose Alzheimer's disease, detection        of two or more polypeptides of the invention can increase the        sensitivity and robustness of the method. Preferably, 1, 2, 3,        4, 5, 10, and, most preferred, all of said polypeptides will be        detected from the same sample. The detection can also be carried        out simultaneously with the detection of other polypeptides        which are preferably also differentially expressed in subjects        having Alzheimer's disease as compared to healthy subjects.        “Assessing the state of Alzheimer's disease” shall be understood        as diagnosing the presence of Alzheimer's disease in a subject        or a patient, as assessing the progression of the disease in a        subject or a patient, and/or as assessing the proneness of a        subject to develop Alzheimer's disease.    -   2. The invention further relates to the method of point 1 in        which 2, or 3, or 4, or 5 polypeptides of said group of peptides        are detected. The invention further relates to a method of point        1 in which 2, or 3, or 4, or 5, or 10 or all polypeptides of        said group of peptides are detected.    -   3. The invention further relates to a method of assessing the        state of Alzheimer's disease in a subject comprising detection        of at least one polypeptide comprising the sequence of SEQ ID        NO:1, SEQ ID NO:2, SEQ II) NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ        ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,        SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID        NO:15, and/or SEQ 1D NO:16. The invention further relates to a        method of assessing the state of Alzheimer's disease in a        subject comprising detection of at least one polypeptide        comprising the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID        NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID        NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ        ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and/or SEQ        ID NO:17. Whereas detection of one such polypeptide is in most        cases sufficient to reliably diagnose Alzheimer's disease,        detection of two or more polypeptides of the invention can        increase the sensitivity and robustness of the method.        Preferably, 1, 2, 3, 4, 5, 10, or all of said polypeptides will        be detected from the same sample. The detection can also be        carried out simultaneously with the detection of other        polypeptides which are preferably also differentially expressed        in subjects having Alzheimer's disease as compared to healthy        subjects.    -   4. The invention further relates to a method of assessing the        state of Alzheimer's disease in a subject comprising detection        of at least one polypeptide comprised. in a group of        polypeptides consisting of        -   i) human cystatin C,        -   ii) human beta-2-microglobulin,        -   iii) human myoglobin (new variant),        -   iv) a fragment of at least 5, 8, 10, or 20 amino acids of            human cystatin C,        -   v) a fragment of at least 5, 8, 10, or 20 amino acids of            human beta-2-microglobulin, and        -   vi) a fragment of at least 5, 8, 10, or 20 amino acids of            human myoglobin (new variant).    -   The invention further relates to a method of assessing the state        of Alzheimer's disease in a subject comprising detection of at        least one polypeptide comprised in a group of polypeptides        consisting of        -   i) human cystatin C,        -   ii) human beta-2-microglobulin,        -   iii) human myoglobin (new variant),        -   iv) human neurosecretory protein VGF,        -   v) a fragment of at least 5, 8, 10, or 20 amino acids of            human cystatin C,        -   vi) a fragment of at least 5, 8, 10, or 20 amino acids of            human beta-2-microglobulin,        -   vii) a fragment of at least 5, 8, 10, or 20 amino acids of            human myoglobin (new variant), and        -   viii) a fragment of at least 5, 8, 10, or 20 amino acids of            neurosecretory protein VGF.    -   Whereas detection of one such polypeptide is in most cases        sufficient to reliably diagnose Alzheimer's disease, detection        of two or more of said polypeptides can increase the sensitivity        and robustness of the method. Preferably, 1, 2, 3, 4, 5, or 6 of        said polypeptides will be detected from the same sample. More        preferably, 1, 2, 3, 4, 5, 6 or all of said polypeptides will be        detected from the same sample. The detection can also be carried        out simultaneously with the detection of other polypeptides        which are preferably also differentially expressed in subjects        having Alzheimer's disease as compared to healthy subjects.    -   5. The invention further relates to a method of investigating        the progression of Alzheimer's disease in a subject        characterised in that a method of any of points 1. to 4 is        performed with at least two distinct samples drawn from the same        subject. For this purpose, samples drawn from a subject at        different points in time will be analysed. Changes in the amount        of the respective polypepfide(s) will allow to draw conclusions        on the progression of Alzheimer's disease in the subject.    -   6. The invention further relates to a method of any of points 1        to 5, wherein detection of said polypeptide(s) is by SELDI-TOF        MS. Other suitable mass spectrometric methods and other methods        of detection can alternatively be used. More specifically, the        invention relates to a method of any of points 1 to 5, wherein        detection of said polypepticle(s) is by SELDI-TOF MS in which        the hydrophobic H50, the WCX2, or the IMAC surface is used as a        support upon ionisation. Different supports for ionisation yield        different sensitivity for specific proteins of interest.    -   7. The invention further relates to a method of any of points 1        to 5, wherein specific antibodies or antibodies recognising said        polypeptide(s) are used for detection of said polyp eptide(s).    -   8. The invention further relates to a method of any of points 1        to 7, wherein detection is in a sample comprising CSF of said        patient. A sample drawn from a subject can be processed        immediately after it has been taken, or it can first be frozen        and be analysed later. Samples may also consist of or contain        other body fluids such as blood, serum, plasma, urine, seminal        plasma, nipple fluid, or cell extracts.    -   9. The invention further relates to a kit comprising a        polypeptide having a molecular mass of 4824±20 Da, a polypeptide        having a molecular mass of 7691±20 Da, a polypeptide having a        molecular mass of 11787±20 Da, a polypeptide having a molecular        mass of 11988±20 Da, and/or a polypeptide having a molecular        mass of 13416±20 Da. The invention further relates to a kit        comprising a polypeptide having a molecular mass of 4824±20 Da,        a polypeptide having a molecular mass of 7691±20 Da, a        polypeptide having a molecular mass of 11787±20 Da, a        polypeptide having a molecular mass of 11988±20 Da, and a        polypeptide having a molecular mass of 13416±20 Da. The        invention further relates to a kit comprising polypeptides        having a molecular mass of 4824±±20 Da, of 7691±20 Da, of        11787±20 Da, of 11988±20 Da, of 13416±20 Da, of 4769±20 Da, of        6958±20 Da, of 6991±20 Da, of 13412±20 Da, of 13787±20 Da, of        17276±20 Da, of 40437±20 Da, of 6895±20 Da, of 6928±20 Da, of        7691±20 Da, of 7769±20 Da, of 7934±20 Da, of 5082±20 Da, of        6267±20 Da, of 6518±20 Da, of 7274±20 Da, and/or of 8209±20 Da.        Such a kit can be applied for various purposes, e.g., for use as        a standard in one of the above mentioned methods. Said kit can        comprise 2, 5, 10, or all of the above polypeptides.    -   10. The invention further relates to a kit comprising a fragment        of at least 5 amino acids of human cystatin C, a fragment of at        least 5 amino acids of human beta-2-microglobulin, and a        fragment of at least 5 amino acids of human myoglobin. This kit        can be applied for various purposes, e.g., for use as a standard        in one of the above mentioned methods. The invention further        relates to a kit comprising a fragment of at least 5, 10 or 20        amino acids of human cystatin C, a fragment of at least 5, 10 or        20 amino acids of human beta-2-microglobulin, a fragment of at        least 5, 10 or 20 amino acids of human myoglobin, and a fragment        of at least 5, 10 or 20 amino acids of neurosecretory protein        VGF. These kits can be applied for various purposes, e.g., for        use as a standard in one of the above mentioned methods.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Average intensities of the five marker peptides of Table 1,which are differentially expressed in the diseased group when comparedto the control groups.

EXAMPLES

The invention is further described by one or several of the followingexamples. These examples are not to be understood as restricting thescope of the invention to the examples by any means.

Example 1 Patients Evaluation and CSF Sampling

Diagnosis of Alzheimer's disease in human subjects was made according tocriteria of the National Institute of Neurologic and CommunicativeDisorders and Stroke-Alzheimer's disease and Related DisordersAssociation (NINCDS-ADRDA). The Alzheimer's disease group consisted of 9patients aged 75±7 years, six men and three women. The group of healthycontrol subjects consisted of 10 individuals aged 78±14 years, two menand eight women with no history, symptoms or signs of psychiatric orneurological disease.

Informed consent was given by each patient and the patients' caregiversbefore the investigation. The study was approved by the local ethicscommittee. After lumbar puncture, CSF samples were frozen on dry iceimmediately upon withdrawal at the bedside in 0.5 ml aliquots and storedat −80° C. until analyses.

Example 2 ProteinChip SELDI Analysis of CSF on SAX2 Chip

SAX 2 Proteinchip array (Ciphergen Biosystems, Fremont, Calif., USA)were equilibrated for 5 min with 5 μl of binding buffer (100 mM NaAcetate pH=4.0). The buffer was carefully removed with an handkerchiefand 2.5 μl of binding buffer was added to the wells. Crude CSF samples(2.5 μl ) were added to the wells and incubated for 20 min at roomtemperature in a humidity chamber on a rocking platform. CSF was removedand the wells were individually washed with 10 μl of binding buffer for5 min. The arrays were then placed in a 15 ml conical Eppendorf andwashed twice with the binding buffer for 5 min. Finally, the chip wasrinsed twice with distilled water, Excess of H₂O was removed and whilethe surface was still moist, two additions per well of 0.5 μl ofsinapinic acid. (SPA) (2 mg/ml) in 50% (vol/vol) acetonitrile and 0.5%(vol/vol) trifluoroacetic acid was perfothied and dried. The arrays werethen read in a ProteinChip reader system, PBS II series (CiphergenBiosystems). The laser beam was focused on the sample in vacuo. Thiscaused the proteins absorbed to the matrix to become ionised and,simultaneously to be desorbed from the Proteinchip array surface. Theionised proteins were detected and their molecular masses weredetermined according to their time-of-flight (TOF). TOF mass spectra,collected in the positive ion mode were generated using an average of 65laser shots throughout the spot at a laser power set slightly abovethreshold (10-15% higher than the threshold) High mass to acquire wasset at 40 kDa, optimised from 1 to 15 kDa. Spectra were collected andanalysed using the Ciphergen Proteinchip (version 3.0) software.External calibration of the reader was performed using the “all-in-1”peptide molecular weight standards (Ciphergen biosystems, Inc.) dilutedin the SPA matrix (1:1, vol/vol) and directly applied onto a well.Protein profile comparison was performed after normalisation on totalion current of all the spectra included in the same experiment. Thereproducibility was tested by analysing different aliquots of the sameCSF sample on 4 different wells of the same proteinchip array(intraassay intrachip reproducibility), on two different chips(intraassay interchip reproducibility) processed in parallel, andreproduced in an other experiment (interassay reproducibility).

Analysis of CSF samples from 9 patients diagnosed with Alzheimer'sdisease relative to 10 controls revealed that 5 peaks were significantlydifferentially expressed between the two groups (p<0.05). Theapproximate average SELDI mass associated with the five differentiallyexpressed proteins was 4.82 kDa, 7.7 kDa, 11.8 kDa and 12.0 kDa and 13.4kDa (p<0.05) (see Table 1, FIG. 1).

Example 3 Strong Anionic Exchange Chromatography (SAX) Purification

In order to identify the proteins corresponding to these peaks, afractionation of crude CSF on a SAX spin column was performed. Theelated fractions were analysed by SELDI-TOF MS.

SAX spin column, lot number SAX2-001116-01, (Ciphergen Biosystems,Fremont, Calif., USA) was rehydrated overnight at 4° C. in theequilibration buffer (20 mM tris(hydroxymethyl)aminomethanehydrochloride (Tris-HCl), 5 mM NaCl, pH 9.0). The column was warmed upat room temperature and air bubbles were removed. The equilibrationbuffer was let flow through column matrix by gravity. Equilibrationbuffer (0.5 ml) was added to the column and passed through the resintwice. Two ml of control CSF was diluted in the equilibration buffer(1:1, vol/vol). Protein sample was loaded to the column by fraction of0.8 ml and allowed to run through the column by gravity until no dropscame out of the column. The column was then centrifuged at 150×g for 1min. The resin was then washed with an equivalent volume ofequilibration buffer. This step was repeated several times in order toload the whole sample onto the resin. Elution of the bound proteins wasperformed by decreasing the pH. Elution buffer A consisted of 20 mMTris-HCl, 5 mM NaCl pH 8.0; elution buffer B=20 mM sodium phosphate pH7.0; elution buffer C=20 mM sodium phosphate pH 6.0; elution buffer D=20mM sodium phosphate and citrate pH 5.0; elution buffer E=20 mM sodiumphosphate and citrate pH 4.0; elution buffer F=20 mM sodium phosphateand citrate pH 3.4; elution buffer G=30% acetonitrile in elution bufferF. Elution was performed by applying 2×75 μl of the elution buffer andcentrifugation at 150×g for 1 min. Each collected fraction (150 μl) wasconcentrated on a speed-vac to a volume of 10 μl. Protein profiles wereanalysed on SELDI-TOF MS using SAX 2 Proteinchip arrays. The chip wasequilibrated with a binding buffer consisting of 20 mM Tris-HCl, 5 nMNaCl, pH=9.0. An aliquot of 0.5 μl of each concentrated fraction wasapplied directly onto 2.5 μl of binding buffer per spot and processed aspreviously described. The rest of the fractions were loaded onto a Tristricine gel as described below.

The differentially expressed peak of 13.4 kDa was eluted with buffer A(20 mM Tris-HCl 5 mM NaCl pH 8.0) and B (20 mM sodium phosphate pH 7.0).The differentially expressed peaks of 11.8 kDa and 12.0 kDa were foundin the fraction eluted with buffer C (20 mM sodium phosphate pH 6.0) andD (20 mM sodium phosphate and citrate pH 5.0). The cluster of 7.7 kDawas eluted with buffer D (20 mM sodium phosphate and citrate pH 5.0) andE (20 mM sodium phosphate and citrate pH 4.0).

Each eluted fraction was loaded on a 16.5% Tris Tricine sodium dodecylsulfate polyacrylamide gel and electrophoresed (SDS PAGE). Aftercoloration with coomassie blue, the bands seen on the gel confirmed theresults obtained by SELDI analysis. The band corresponding to thecluster of 7.7 kDa, 11.8 kDa and 12.0 kDa were cut out. Proteins wereextracted as described in Example 6 and identified by Q-TOF. The 7.7 kDapeak MS analysis did not match with any known human protein, however,may indicate to a new variant or homologue of myoglobin. Peptidesequences were the following

XXAD(L/I)AGHG(Q/K)EV(L/I)(L/I)R and HGTVV(L/I)TA(L/I)GG(L/I)(L/I)K.

The MS analysis of the 11.8 kDa and 12.0 kDa peaks identifiedbeta-2-microglobulin for both of them.

Since the cluster of 13.4 kDa could not be seen on the Tris Tricine gel,a Tris glycine SDS-PAGE electrophoresis was performed on crude CSFsamples. The band corresponding to the beta-2-microglobulin could beeasily found on this stained get We concluded that the protein migratingjust above the beta-2-microglobulin could correspond to the nextabundant protein seen on the SELDI profile, namely the 13.4 kDa peak.The band was excised from the gel and digested by trypsin before MALDIanalysis. The peptide mass fingerprint analysis allowed to identify theCystatin C. The sequence coverage provided by the analysis was 60%.

Example 4 Monodimensional Electrophoresis/Tris Glycine Gels

Twenty μl of CSF were mixed with 10 μl of denaturing Laemmli buffer[Laemmli 1970]. The samples were heated to 95° C. for 5 min, and loadedon a 15% T (T=total acrylamide concentration) SDS-polyacrylamide gelaccording to the method of Laemmli. Gels were stained in a solutioncontaining Coomassie Brilliant Blue R-250 (0.1% w/v) and methanol (50%v/v) for 30 min. Destaining was clone in a solution containing methanol(40% v/v) and acetic acid (10% v/v).

Example 5 Monodimensional Electrophoresis: Tris Tricine Gels

Tris tricine SDS-PAGE electrophoresis was performed according toSchagger and von Jagow [1987] using precast 16.5% T gels (Biorad,Hercules, Calif.). The anode buffer consisted of 0.2M Tris-HCl, pH 8.9and the cathode buffer consisted of 0.1M Tris-HCl, 0.1M Tricine, 0.1%SDS, pH 8.25. Samples were diluted in 10 μl of 50 mM of bromophenolblue, pH 6.8. After denaturation at 95° C. for 5 min, samples wereloaded onto the gel. Gels were run at 80V for 3 hours. Afterelectrophoresis, gels were fixed in 40% methanol, 10% acetic acid for30min. Gels were then stained with Colloidal blue coomassie G250overnight and destained in 30% methanol. Bands to be identified wereimmediately cut, placed in an eppendorf and kept at 4° C. until furtheranalysis. The apparent molecular masses were determined by runningpolypeptide molecular weight (MW) standards: Triosephophate isomerase MW26,625; Myoglobin MW 16,950; α-lactalbumin MW 14,437; Aprotinin MW6,512; Insulin b chain, oxidised MW 3,496 and Bacitracin MW 1,423(Biorad).

Example 6 Protein Digestion and Peptide Extraction [Bienvenu 1999]

Fragments of gels containing proteins of interest were cut out fordigestion of the proteins with trypsin using previous publishedprocedures [Shevchenko 1996, Hellman 1994, Rosenfeld 1992] and modifiedas described below. The piece of gel was first destained with 100 μl of50 mM ammonium bicarbonate, 30% (v/v) acetonitrile during 15 min at roomtemperature. Destaining solution was removed and replaced by 25 μl of 10mM DL-dithiothreitol (DTT) in 50 mM ammonium bicarbonate and incubated35 min at 56° C. DTT solution was then replaced by 25 μl of 55 mMiodoacetamide in 50 mM ammonium bicarbonate and incubated during 45 minat room temperature in the dark. Gel pieces were washed for 10 min with100 μl of 50 mM ammonium bicarbonate and for 10 min with 100 μl of 50 mMammonium bicarbonate and 30% (v/v) acetonitrile.

Gel pieces were then dried for 30 min in a Hetovac vacuum centrifuge(HETO, Allerod, Denmark). Dried pieces of gel were rehydrated for 45 minat 4° C. in 5-20 μl of a solution of 50 mM ammonium bicarbonatecontaining trypsin at 6.25 ng/μl. After an over-night incubation at 37°C., gel pieces were dried under high vacuum centrifuge before beingrehydrated by the addition of 20 μl of distilled water and finally driedagain in a speed-vac for 30 min. Extraction of the peptides wasperformed with 20 μl of 0.1% (v/v) trifluoroacetic acid (TEA) for 20 minat room temperature with occasional shaking. The TFA solution containingthe peptides was transferred to a polypropylene tube. A second elutionwas performed with 20 μl of 0.1% (v/v) TFA in 50% (v/v) acetonitrile for20 min at room temperature with occasional shaking The second TFAsolution was pooled with the first one. The volume of the pooledextracts was reduced to 1-2 μl by evaporation under vacuum. Controlextractions (blanks) were performed using pieces of gels devoid ofproteins.

Example 7 Protein Identification by Peptide Mass Fingerprinting Analysis

1.5 μl of sample was placed on a MALDI 100-well target plate. Samevolumes of matrix (10 mg/ml cc-Cyano-4-hydroxycinnamic acid in 50% (v/v)acetonitrile, 0.1% (v/v) TFA) were added to the previously loadeddigest. Samples were dried as quickly as possible using a vacuumcontainer. Mass measurement from liquid solution were conducted with aMALDI-TOF mass spectrometer Voyager™ Elite and Super STR (PerSeptiveBiosystems, Framingham Mass., USA) equipped with a 337 nm nitrogenlaser. The analyser was used in the reflectron mode at an acceleratingvoltage of 20 kV, a delayed extraction parameter of 100-140 ns and a lowmass gate of 850 Da. Laser power was set slightly above threshold(10-15% higher than the threshold) for molecular ion production. Spectrawere obtained by summation of 10 to 256 consecutive laser shots. Massesof the 60 highest peaks were extracted from the spectra and used forprotein identification using the SmartIdent peptide mass fingerprinttool [Gras 1999]. The research was conducted against SWISS-PROT andTrEMBL databases. The query was made for the human, the minimum numberof matched masses was 4, the maximal tolerance for masses was 50 ppmafter an internal calibration using autolysis product of trypsin, atmost one missed cleavage for tryptic peptides was allowed, and themodifications accepted were carboxymethylation with iodoacetamide ofcysteines and ariefactual oxidation of methionines.

Example 8 Protein Identification by Peptide Fragmentation Analysis

Prior to nanoLC (LC=liquid chromatography) separation, the volumes ofpeptide containing solutions were adjusted to 7 μl by addition of a 0.1%(v/v) formic acid solution. Samples were settled in a Triathlonautosampler (Spach, Emmen, Holland) For each experiment, 5 μl of peptidecontaining solution were injected on a C18 reverse phase column of 75 μminner diameter (YMS-ODS-AQ200, Michrom Bioresource, Auburn, Calif.).Peptides were eluted with an acetonitrile (ACN) gradient in the presenceof 0.1% (v/v) formic acid, using SunFlow pumps (SunChrom,Friderichsdorf, Germany). A flow splitter was used in order to decreasethe flow rate after the pumps from 200 to 0.4 μl/min. Peptides wereanalysed with a quadrupole time-of-flight (Q-TOF) mass spectrometer(Micromass, Wythenshawe, England). A 2700 V tension was applied on thenanoelectrospray capillary (New Objective, Woburn, Mass., USA). Argonwas used as collision gas. The collision energy was settled as afunction of the precursor ion mass. MS/MS spectra were acquired byautomatic switching between MS and MS/MS mode. Acquired MS/MS data wereconverted in a compatible format (DTA files) by ProteinLynx software(Micromass, Wythenshawe, England) and analysed using conventional searchengines against SWISS-PROT, TrEMBL, NCBTInr and EST databases. In casesof manual inter-pretation of MS/MS data, identification was performed bysequence only search.

It was found that marker M5 was a fragment of Cystatin C, markers M3 andM4 were isoforms of beta-2-microglobulin and M2 was a new variant orhomologue of myoglobin. Marker M1 was found to be a fragment of theneurosecretory protein VGF.

Example 9 Statistical Analysis

P-values were calculated using standard statistical methods known to theperson skilled in the art. P-values smaller than 0.05 were considered tobe statistically significant.

Example 10 Isolation of the 4.8 kDa Fragment (Marker M1)

Some CSF samples from control patients were fractionated by Centricon 30filtration device (Millipore Corp., Bedford, Mass.) in order to removethe protein with a molecular weight higher than 30 kDa. The salt andpolypeptide with a molecular weight lower than 3 kDa were removed usinga Centricon 3 (Millipore Corp., Bedford, Mass.). The Centricon 3 wasthen washed with ultrapure distilled water. In that wash fraction, the4.82 kDa was found to be the major component. This liquid fraction wasfirst reduced with a 10 mM solution of 1,4-Dithioerythritol for 1 h at56° C., then alkylated with 54 mM iodoacetamide for 45 min at roomtemperature. Finally, the polypeptide was digested with 6 mg/l trypsinovernight at 37° C. This liquid fraction was analysed by nanoLC andQ-TOF as previously described.

Example 11 Different Surface Materials for SELDI-TOF Analysis

Using SELDI-TOF, an analysis of 10 CSF samples from AD patients and 10controls was performed on three different surfaces: the hydrophobic H50,the WCX2, and the IMAC surface (Ciphergen Biosystems, Fremont, Calif.,USA, resp.). Seven differentially expressed peaks were found on the1150, five markers on the WCX2, and five markers on the MAC surface. Adiagnostic test using the markers on the H50 chip revealed a specificityand sensitivity of 100% and 70%, respectively. The combination of themarkers found on H50 and WCX2 gave a specificity and sensitivity of 100%and 80%. Finally, the combination of the markers found on H50, WCX2 andLMAC gave a specificity and sensitivity of 100% and 90%.

The average masses of the differentially expressed polypeptides asdetermined by SELDI-TOF using different surface materials were asfollows:

Surface hydrophobic H50: 7 peaks

Marker 1: 4769±s.d. Da

Marker 2: 6958÷s.d. Da

Marker 3: 6991÷s.d. Da

Marker 4: 13412±s.d. Da

Marker 5: 13787±s.d. Da

Marker 6: 17276±s.d. Da

Marker 7: 40437±s.d. Da

Surface IMAC Cu: 5 peaks

Marker 1: 6895±s.d. Da

Marker 2: 6928±s.d.Da

Marker 3: 7691±s.d. Da

Marker 4: 7769±s.d. Da

Marker 5: 7934±s.d. Da

Surface WCX2: 5 peaks

Marker 1: 5082±s.d. Da

Marker 2: 6267±s.d. Da

Marker 3: 6518±s.d. Da

Marker 4: 7274±s.d. Da

Marker 5: 8209±s.d. Da

The standard deviation (s.d.) is 20 Da for each marker above. However,the standard deviation can also be 40 Da, or 10 Da, or 5 Da for eachmarker above.

BIBLIOGRAPHY,

Adam, B. L. et al. 2001, Proteomics 1(10): 1264-1270

Asgeirsson B, Haebel S, Thorsteinsson L, Helgason E, Gudmundsson K O,Gudmundsson G, Roepstorff P. Hereditary cystatin C amyloid angiopathy:monitoring the presence of the Leu68Gln cystatin C variant incerebrospinal fluid and monocyte cultures by M S. Biochem S. 1998, 329,497-503.

Beyer K, Lao J I, Gomez M, Riutort N, Latorre P, Mate J L, Ariza A.Alzheimer's disease and the cystatin C gene polymorphism: an associationstudy. Neuroscience letters. 2001, 315, 17-20,

Canu N, Possenti R, Ricco A S, Rocchi M, Levi A. Cloning, structuralorganization analysis, and chromosomal assignment of the human gene forthe neurosecretory protein VGF. Genomics 1997, 45 (2), 443-446.

Cohen D H, Feiner H, Jenson O, Frangione B. Amyloid fibril in hereditarycerebral hemorrhage with amyloidosis (HCHWA-I) is related to thegastroentero-pancreatic neuroendocrine protein. J. Exp. Med. 1983, 158,623-628.

Current Protocols in Immunology, Eds. Coligan J E, Kruisbeek A M,Margulies D H, Shevach E M, and Strober W., John Wiley & Sons Inc, 1991

Crawford U, Freeman M I, Schinka J A, Abdullah L I, Gold M, Hartman R,Krivian K, Morris M D, Richards D, Duara R, Anand R, Mullan M J. Apolymorphism in the cystatin C gene is a novel rsik factor forlate-onset Alzheimer's disease. Neurology. 2000, 55, 763-768.

Davies, H. A. 2000. The ProteinChip(R) System from Ciphergen: A newtechnique for rapid, micro-scale protein biology. J. Molecular Medicine,78 (7):B29 Deng A, Irizarry M C, Nitsch R M, Growdon J H, Rebeck G W.Elevation of Cystatin C in susceptible neurons in Alzheimer's disease.Am. J Pathol. 2001, 159, 1061-1068.

Ernerudh J, Olsson T, Berlin G, von Schenck H. Cerebrospinal fluidimmunoglobulins and beta 2-microglobulin in lymphoproliferative andother neoplastic diseases of the central nervous system. Arch Neurol,1987, 44(9), 915-20.

Finckh U, Von der Kammer H, Velden I, Michel T, Andresen B, Deng A,Zhang J, Muller-Thomsen T, Zuchowski K, Menzer G, Mann U,Papassotiropoulos A, Heun R, Zurdel J, Hoist F, benussi L, Stoppe G,Reiss J, Miserez A R, Staehelin H B, Rebeck W, Hyman B T, Binetti G,Hock C, Growdon J H, Nitsch R M. Genetic association of a cystatin Cgene polymorphism with late-onset Alzheimer's disease. Arch Neurol.2000, 57, 1579-1583.

Francis, P. T. et al. J. Neurol, Neurosurg. Psychiatry 1999, 66(2):137-147 Fung, E T et al. Protein biochips for differential profiling.Current Opinion in Biotechnology, 2001, 12(1): 65-69

Ghiso J, Jensson O, Frangione B. Amyloid fibrils in hereditary cerebralhemorrhage with amyloidosis of Icelandic type is a variant ofgamma-trace basic protein (cystatin C). Proc Natl Acad Sci USA. 1986;83(9):2974-8.

Ghiso J, Pons-Estel B, Frangione B. Hereditary cerebral amyloidangiopathy: the amyloid fibrils contain a protein which is a variant ofcystatin C, an inhibitor of lysosomal cysteine proteases. BiochemBiophys Res Commun 1986; 136(2):548-54.

Gras R, Müller M, Gasteiger E, Gay S, Binz P A, Bienvenut W V, HooglandC, Sanchez J C, Bairoch A, Hochstrasser D F, Appel R. Improving proteinidentification from peptide mass fingerprinting through a parameterisedmulti-level scoring algorithm and an optimised peak detection.Electrophoresis 1999, 20: 3535-3550

Grubb A O, Jensson O, Gudmundsson G, Amason A, Lofberg H, Maim J.Abnormal metabolism of g-trace alkaline microprotein. The basic defectin hereditary cerebral hemorrhage with amyloidosis. N. Engl. J. Med1984, 311, 1547-1549.

Hellman U, Wernstedt C, Góñez, J, Heldin C H. Improvement of an “In-Gel”digestion procedure for the micropreparation of internal proteinfragments for amino acid sequencing. Anal. Biochem. 1995, 224, 451-5.

Hoekman K, Van Nieuwkoop J A, Willemze R. The significance of beta-2microglobulin in clinical medicine. Neth J Med. 1985;28(12):551-7.

Huse W D, Sastry L, Iverson S A, Kang A S, Alting-Mees M, Burton D R,Benkovic S J, Lerner R A. Generation of a large combinatorial library ofthe immunoglobulin repertoire in phage lambda. 1989, Science 246:1275-1281.

Issaq H J, Veenstra T D, Conrads T P, Felschow D. The SELDI-TOF MSapproach to proteomics: protein profiling and biomarker identification.Biochem. Biophys. Res. Commun. 2002, 292 (3): 587-592

Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z. Serum andCerebrospinal fluid cystatin C levels in vascular and Alzheimer'sdementia. Acta Neurol. Scand. 2000, 101, 279-282.

Laemmli U K. Cleavage of structural proteins during the assembly of thehead of bacteriophage T4. Nature. 1970 Aug. 15; 227(259):680-5.

Leung-Tack J, Tavera C, Gensac M C, Martinez J, Cone A. Modulation ofphagocytosis-associated respiratory burst by human cystatin C: role ofthe N-terminal tetrapeptide Lys-Pro-Pro-Arg, Exp. Cell Research. 1990,188, 16-22.

Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F,Codeposition of cystatin C with amyloid-beta protein in the brain ofAlzheimer's disease patients. J. Neuropathol Exp Neural 2001, 60, 94-104

Merchant M, Weinberger S R. Recent advancements in surface-enhancedlaser . desorption/ionization-time of flight-mass spectrometry.Electrophoresis, 2000, 21: 1164-1167

Popovic T, Brzin J, Ritonja A, Turk V. Different forms of human CystatinC. Biol. Chem. Hoppe-Seyler. 1990, 371, 575-580.

Raymackers J, Daniels A, DeBrabandere V, Missiaen C, Dauwe M, VerhaertP, Vanmechelen E, Meheus L. Identification of two dimensionallyseparated human cerebrospinal fluid proteins by N-terminal sequencing,matrix-assisted laser-desorption/ionization-mass spectrometry,nanoliquid chromatography-electrospray ionization-time of flight-massspectrometry, and tandem mass spectrometry. Electrophoresis, 2000, 21,2266-2283.

The Ronald and Nancy Reagan Research Institue of the Alzheimer'sAssociation and the National Institute on Aging Working Group. ConsensusReport of the Working Group on: “Molecular and Biochemical Markers ofAlzheimer's Disease”. Neurobiology of Aging, 1988, 19 (2): 109-116.

Robles A. Some Remarks on biological markers of Alzheimer's Disease.Neurobiology of Aging, 1998, 19 (2): 153-157

Rosenfeld J, Capdevielle J, Guillemot J C, Ferrara P. In-gel digestionof proteins for internal sequence analysis after one- or two-dimensionalgel electrophoresis. Anal. Biochem. 1992, 203, 173-9.

Shevchenko A, Whim M, Vorm O, Mann M. Mass spectrometric sequencing ofproteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68,850-8.

Teunissen C E, de Vente J, Steinbusch H W M, De Bruijn C. Neurobiologyof Aging, 2002, 23: 485-508

U.S. Pat. No. 4,366,241

U.S. Pat. No. 4,376,110

U.S. Pat. No. 4,517,288

U.S. Pat. No. 4,837,168

Ward E S et al., Binding activities of a repertoire of singleimmunoglobulin variable domains secreted from Escherichia coli. Nature1989, 341, 544-546

Wei L, Berman Y, Castano E M, Cadene M, Beavis R C, Devi L, Levy E.Instability of the amyloidogenic cystatin. C variant of hereditarycerebral hemorrhage with amyloidosis, Icelandic type. J. Biol. Chem.1998, 273, 11806-11814.

Wulfkuhle J D, McLean K C, Paweletz C P, Sgroi D C, Trock B J, Steeg PS, Petricoin E F, New approaches to proteomic analysis of breast cancer.Proteomics 2001, 1 (10): 1205-1215

Xiao Z, Adam B L, Cazares L H, Clements M A, Davis J W, Schellhammer PF, Dalmasso E A, Wright G L. Quantitation of serum prostate-specificmembrane antigen by a novel protein biochip immunoassay discriminatesbenign from malignant prostate disease. 2001, Cancer Research 61 (16):6029-6033

1. (canceled)
 2. An isolated polypeptide having the amino acid sequenceof SEQ ID NO:
 17. 3. A method for assessing the state of Alzheimer'sdisease in a subject, wherein the method comprises detecting in a samplefrom the subject at least one polypeptide from each of the followinggroups: a) a polypeptide having an amino acid sequence selected from thegroup consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16;b) a polypeptide having the amino acid sequence selected from the groupconsisting of SEQ ID NO: 3, 4, 5, and 6; and c) a polypeptide having theamino acid sequence of SEQ ID NO:
 17. 4. The method of claim 3, whereinthe method further comprises contacting the sample with an antibody thatspecifically binds one of the polypeptides.
 5. The method of claim 3,wherein at least one polypeptide is detected by SELDI-TOF MS.
 6. Themethod of claim 3, wherein the method is performed on at least twosamples from the subject.
 7. The method of claim 3, wherein the sampleis CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, orcell extract.
 8. The method of claim 3, wherein the polypeptides aredetected in one sample from the subject.
 9. A method for assessing thestate of Alzheimer's disease in a subject, wherein the method comprisesdetecting in a sample from the subject at least three distinctpolypeptides, wherein a first polypeptide is selected from the groupconsisting of SEQ ID NO: 3, 4, 5, 6, 7 and 17; and wherein a secondpolypeptide and a third polypeptide are selected from the groupconsisting of: a) a polypeptide having the amino acid sequence selectedfrom the group consisting SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, or 17; b) a human cystatin C; c) a humanbeta-2-microglobulin; d) a 7.7 kD homologue of human myoglobin; e)neurosecretory protein VGF; f) a fragment of at least 5 amino acids ofhuman cystatin C; g) a fragment of at least 5 amino acids of humanbeta-2-microglobulin; h) a fragment of at least 5 amino acids of the 7.7kD homologue of human myoglobin; and i) a fragment of at least 5 aminoacids of neurosecretory protein VGF.
 10. The method of claim 9, whereinthe method further comprises contacting the sample with an antibody thatspecifically binds one of the polypeptides.
 11. The method of claim 9,wherein at least one polypeptide is detected by SELDI-TOF MS.
 12. Themethod of claim 9, wherein the method is performed on at least twosamples from the subject.
 13. The method of claim 9, wherein the sampleis CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, orcell extract.
 14. The method of claim 9, wherein the polypeptides aredetected in one sample from the subject.
 15. The method of claim 9,wherein the method comprises detecting at least four distinctpolypeptides, wherein a fourth polypeptide is selected from the groupconsisting of: a) a polypeptide having the amino acid sequence selectedfrom the group consisting SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, or 17; b) a human cystatin C; c) a humanbeta-2-microglobulin; d) a 7.7 kD homologue of human myoglobin; e)neurosecretory protein VGF; f) a fragment of at least 5 amino acids ofhuman cystatin C; g) a fragment of at least 5 amino acids of humanbeta-2-microglobulin; h) a fragment of at least 5 amino acids of the 7.7kD homologue of human myoglobin; and i) a fragment of at least 5 aminoacids of neurosecretory protein VGF.
 16. The method of claim 15, whereinthe polypeptides are detected in one sample from the subject.
 17. Themethod of claim 15, wherein the method comprises detecting at least fivedistinct polypeptides, wherein a fifth polypeptide is selected from thegroup consisting of: a) a polypeptide having the amino acid sequenceselected from the group consisting SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, or 17; b) a human cystatin C; c) a humanbeta-2-microglobulin; d) a 7.7 kD homologue of human myoglobin; e)neurosecretory protein VGF; f) a fragment of at least 5 amino acids ofhuman cystatin C; g) a fragment of at least 5 amino acids of humanbeta-2-microglobulin; h) a fragment of at least 5 amino acids of the 7.7kD homologue of human myoglobin; and i) a fragment of at least 5 aminoacids of neurosecretory protein VGF.
 18. The method of claim 17, whereinthe polypeptides are detected in one sample from the subject.